Leading Cancer Researcher, Jerome E. Groopman, Appointed to Genta's Board of Directors
BERKELEY HEIGHTS, N.J., Nov. 27 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq:GNTA) today announced the appointment of Jerome E. Groopman, M.D., to the Company's Board of Directors. Dr. Groopman, who is Professor of Medicine and Chief of Experimental Medicine at the Beth Israel Deaconess Medical Center in Boston, also holds the Dina and Raphael Recanati Chair of Medicine at Harvard.
Dr. Groopman has an extensive record of achievement in basic and clinical research related to cancer, hematology, and HIV infection. He has served on the Advisory Council to the National Heart, Lung and Blood Institute (NHLBI) for AIDS-related diseases. He was Chairman of the Advisory Committee to the Food and Drug Administration (FDA) for Biological Response Modifiers. In 2000, Dr. Groopman was elected to the Institute of Medicine of the National Academy of Sciences. Dr. Groopman also serves on many scientific editorial boards and has authored has published more than 150 scientific articles. Recently, he has written two books related to the devastating personal impact of disease in people afflicted with AIDS and cancer entitled, "The Measure of Our Days," and "Second Opinions: Stories of Intuition and Choice in the Changing World of Medicine." Among other periodicals, he is a frequent contributor to The New Yorker magazine, where he is staff writer on medicine and biology. Dr. Groopman received B.A. and M.D. degrees from Columbia University, completed internal medicine residency at the Massachusetts General Hospital, and underwent subspecialty fellowship training in hematology and oncology at UCLA and the Dana Farber Cancer Institute.
"Dr. Groopman joins the Board at a pivotal time for Genta. His expertise in research, clinical, and regulatory affairs will make a critical contribution as we move toward the successful commercialization of our leading anticancer compounds," stated Dr. Raymond P. Warrell, Jr., Genta's Chairman of the Board and Chief Executive Officer. "Supporting Genta's efforts in transforming research programs into clinical options for cancer patients is an exciting prospect for me," stated Dr. Groopman. "I look forward to sharing my insights in key areas that will assist the impressive leadership already assembled on the Genta Board."
About Genta
Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on anticancer therapy. The Company's research platform is anchored by oligonucleotide chemistry, particularly applications of antisense and decoy aptamer technology. Genasense(TM), the Company's lead compound, is being developed in collaboration with Aventis and is currently undergoing late-stage, Phase 3 clinical testing in several clinical indications. Genta's pipeline also comprises a portfolio of small molecules, including gallium-containing compounds and Androgenics compounds for prostate cancer. For more information about Genta, please visit our website at: genta.com.
The statements contained in this press release that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the expectations, beliefs, intentions or strategies regarding the future. Without limiting the foregoing, the words "anticipates," "believes," "expects," "intends," "may" and "plans" and similar expressions are intended to identify forward-looking statements. The Company intends that all forward-looking statements be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company's views as of the date they are made with respect to future events, but are subject to many risks and uncertainties, which could cause the actual results of the Company to differ materially from any future results expressed or implied by such forward-looking statements. For example, the results obtained in pre-clinical or clinical studies may not be indicative of results that will be obtained in future clinical trials, and delays in the initiation or completion of clinical trials may occur as a result of many factors. Further examples of such risks and uncertainties also include, but are not limited to: the obtaining of sufficient financing to maintain the Company's planned operations; timely development, receipt of necessary regulatory approvals, and acceptance of new products; the successful application of the Company's technology to produce new products; the obtaining of proprietary protection for any such technology and products; the impact of competitive products and pricing and reimbursement policies; and changing market conditions. The Company does not undertake to update forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurances that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement and other factors detailed in the Company's reports filed with the Securities and Exchange Commission.
Make Your Opinion Count - Click Here
tbutton.prnewswire.com
SOURCE Genta Incorporated
CO: Genta Incorporated
ST: New Jersey
SU: PER
prnewswire.com
11/27/2002 08:00 EST |
